Index group 1 : coronary artery disease Index group 2: atrial fibrillation Control group 1: Diabetes/hypertension/hypercholesterolaemia Control group 2: Healthy subjects
Conditions
Interventions
Trade Name: Aspirin 75 mg
Product Name: Aspirin 75 mg
Product Code: BO1AC06
Pharmaceutical Form: Tablet
Trade Name: Clopidogrel (Plavix)
Product Name: Clopidogrel (Plavix)
Pharmaceutical Form: Film-c
Sponsors
Sandwell and West Birmingham NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Index group 1: Stable coronary artery disease Index group 2: Atrial fibrillation Control group 1: Diabetes/hypetension/hypercholesterolaemia Control group 2: Healthy subjects Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Recent acute coronary syndrome or stroke (<3 months) 2. Current use of oral anticoagulantsor antibiotics 3. Bleeding abnormalities e.g von Willebrand's disease 4. Significant hepatic, renal, neoplastic, pyschiatric or connective tissue disease 5. Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Aspirin and clopidogrel are two drugs that are supposed to reduce the risk of having a heart attack or a stroke. However, some people these drugs may not be fully effective. Our objective is to find out if this is the case in two groups at especially high risk of heart attack and stroke - these groups being people with existing coronary artery disease (CAD) or atrial fibrillation (AF);Secondary Objective: 1. To determine the frequency of aspirin resistance in CAD and AF 2. To determine whether or not aspirin resistance is associated with changes in vascular function, inflammation and coagulation. 3. To determine any effects of cessation of the use of clopidogrel (n.b. the protocol does not actively take subjects off the drug - the cessation will be done purely for good clinical reasons).;Primary end point(s): The frequency of aspirin resistance in CAD and AF, and its relationship with vascular function, thrombosis and inflammation. | — |
Countries
United Kingdom
Outcome results
None listed